Navigation Links
Circassia Extends its Clinical-Stage Portfolio With Phase II Trials of T-Cell Vaccines Against House Dust Mite and Cat Allergies
Date:1/19/2010

l regulatory and supply chain benefits. The short peptides utilised in Circassia's vaccines are manufactured chemically, in contrast to existing allergen immunotherapies, which are purified from natural sources. Circassia's approach applies the chemistry, manufacturing and control standards associated with conventional pharmaceuticals to its allergy T-cell vaccines. This fits with changes in the European regulatory environment, where authorities are increasingly treating allergen immunotherapies as pharmaceutical products, and requiring elimination of the batch-to-batch potency variability that is an intrinsic feature of many current treatments.

About Circassia

Circassia has a highly experienced management team with a proven track record in product development and commercialisation. Having successfully completed three fundraising rounds the company is backed by a syndicate of world-class venture capital and institutional investors, including Imperial Innovations, Invesco Perpetual, Goldman Sachs and Lansdowne Partners.

    For more information please visit http://www.circassia.co.uk.

    Contacts
    Steve Harris                             Rob Budge
    CEO                                      RJB Communications
    Circassia                                Tel: +44(0)1865-760969
    Tel: +44(0)1865-784574                   Mobile: +44(0)7710-741241


SOURCE Circassia Ltd


'/>"/>
SOURCE Circassia Ltd
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Circassia Raises GBP15 Million ($25 Million) in Oversubscribed Investment Round
2. Circassia Begins Phase II Clinical Trial With Ragweed Allergy Therapy
3. Circassias Allergy Therapy Begins Phase II Clinical Trial in Asthma Patients
4. Circassia Completes Patient Recruitment for Phase II Clinical Trial of Toleromune(R) Allergy Treatment
5. Circassia Initiates Further Phase II Clinical Study of Toleromune(R) Anti-Allergy Technology
6. Circassia Achieves Successful Phase II Clinical Results With Toleromune(R) Anti-Allergy Technology
7. Cadence Pharmaceuticals Announces FDA Extends New Drug Application Review for Intravenous Acetaminophen by Three Months
8. Applied Seals North America Extends Global Network With Addition of Distributor in Europe
9. Lincare Holdings Inc. Extends Terms of Employment Agreements with Executive Officers
10. Neurosciences Institute Discovers Drug Extends Stroke Treatment Time to 24 Hours, Repairs Brain Tissue
11. FDA Extends Review Period for Daiichi Sankyo, Lilly Investigative Antiplatelet Drug, Prasugrel
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)...  Ascendant Solutions, Inc. (Pink Sheets: ASDS ) ... subsidiary, Dougherty,s Holdings, has acquired Springtown Drug (" ... Springtown, Texas , just north of ... pharmacy has provided retail prescriptions, healthcare products and gifts ... . The Springtown ...
(Date:8/31/2015)... Pa. , Aug. 31, 2015 The ... reversed statewide since Pennsylvania State ... life-saving drug kits, naloxone. Heroin and opioid ... Pennsylvania , killing more individuals than ... approximately 2,400 Pennsylvanians died from a drug overdose. ...
(Date:8/31/2015)... , Aug. 31, 2015 Regen BioPharma, ... development of a novel means of delivering its ... RGBP-248, to liver tumors utilizing a clinically approved ... overcomes previous hurdles with gene silencing therapeutics in ... delivered throughout the whole body.  By utilizing a ...
Breaking Medicine Technology:Ascendant Solutions, Inc. Announces Completion of Fifth Pharmacy Acquisition by Its Dougherty's Holdings Subsidiary 2Ascendant Solutions, Inc. Announces Completion of Fifth Pharmacy Acquisition by Its Dougherty's Holdings Subsidiary 3Departments of Drug & Alcohol Programs and Health Announce Report 289 Pennsylvanian Lives Saved by Naloxone 2Departments of Drug & Alcohol Programs and Health Announce Report 289 Pennsylvanian Lives Saved by Naloxone 3Regen BioPharma, Inc. Develops BORIS Gene Silencing Based Treatment for Unresectable Liver Cancer 2Regen BioPharma, Inc. Develops BORIS Gene Silencing Based Treatment for Unresectable Liver Cancer 3
... June 9 Halozyme Therapeutics,Inc. (Nasdaq: ... products targeting the extracellular matrix, today,announced new ... mellitus program at,the American Diabetes Association,s 68th ... company,s proprietary recombinant human,hyaluronidase enzyme (rHuPH20) with ...
... Pivotal Study Highlighted at Recent Arizona Alzheimer,s ... Consortium Annual Conference in Phoenix -, PHOENIX and ... Health Research Institute today announced that they are,actively enrolling patients ... treatment of Alzheimer,s disease. The study will,evaluate the safety and ...
Cached Medicine Technology:Halozyme Therapeutics Announces Phase I Clinical Trial Results Demonstrating that the Combination of Recombinant Human Hyaluronidase (rHuPH20) With Humulin R(R) and with Humalog(R) Yields Faster, More Physiologic Insulin Kinetics and Better Predictability 2Halozyme Therapeutics Announces Phase I Clinical Trial Results Demonstrating that the Combination of Recombinant Human Hyaluronidase (rHuPH20) With Humulin R(R) and with Humalog(R) Yields Faster, More Physiologic Insulin Kinetics and Better Predictability 3Halozyme Therapeutics Announces Phase I Clinical Trial Results Demonstrating that the Combination of Recombinant Human Hyaluronidase (rHuPH20) With Humulin R(R) and with Humalog(R) Yields Faster, More Physiologic Insulin Kinetics and Better Predictability 4Halozyme Therapeutics Announces Phase I Clinical Trial Results Demonstrating that the Combination of Recombinant Human Hyaluronidase (rHuPH20) With Humulin R(R) and with Humalog(R) Yields Faster, More Physiologic Insulin Kinetics and Better Predictability 5Banner Alzheimer's Institute and Sun Health Research Institute Enrolling Local Patients in Study of Investigational Therapy to Treat Alzheimer's Disease 2Banner Alzheimer's Institute and Sun Health Research Institute Enrolling Local Patients in Study of Investigational Therapy to Treat Alzheimer's Disease 3
(Date:9/1/2015)... ... ... The premier online medical education company for Podiatrists and ... podiatric, surgical and wound care conferences . The Residency Education Summits standardize and ... podium and across the table during hands-on surgical and advanced wound care workshops. ...
(Date:8/31/2015)... ... ... The PT Outcomes Registry is an organized system for collecting data to evaluate ... being developed by the American Physical Therapy Association (APTA). , Al Amato, PT, MBA, ... FOTO Outcomes measures as one of the primary global outcomes measures to be used ...
(Date:8/31/2015)... ... August 31, 2015 , ... Sculpted Contours Luxury Medical Aesthetics ... of Power and Influence by Modern Luxury’s The Atlantan Magazine. , This ... well as Kathy King. Her idea and vision to bring to Atlanta a ...
(Date:8/31/2015)... (PRWEB) , ... August 31, 2015 , ... ... Diabetes Institute (WDI) at Western University of Health Sciences to learn more about ... of Periodontology, School of Dental Sciences and Institute of Cellular Medicine at Newcastle ...
(Date:8/31/2015)... Los Angeles, CA (PRWEB) , ... August 31, 2015 , ... ... August 16 by CDA Press, the expert guest author addressed the topic of treating ... The author explained that, while steroids were shown to slightly improve physical function in ...
Breaking Medicine News(10 mins):Health News:PRESENT e-Learning Systems Announces their 2016 Podiatry and Wound Care Medical Education Conference Schedule 2Health News:FOTO Selected as Official Registry Partner with Physical Therapy Outcomes Registry 2Health News:Sculpted Contours Owner Selected One of Atlanta's Women of Power and Influence by Modern Luxury's The Atlantan Magazine 2Health News:Sculpted Contours Owner Selected One of Atlanta's Women of Power and Influence by Modern Luxury's The Atlantan Magazine 3Health News:Western Diabetes Institute Collaborates with UK team 2Health News:Western Diabetes Institute Collaborates with UK team 3Health News:Western Diabetes Institute Collaborates with UK team 4Health News:Article on Steroid Use for Back Pain Highlights the Effectiveness of Surgery in Treating Disk Pain, says Dr. Seyed M. Rezaian 2
... have found that high doses of the common painkiller like ... a heart attack if taken in high doses for a ... that there was no danger for occasional users, and its ... who depend on it to lead normal lives. They claimed ...
... today dismissed the medical negligence claim to the tune ... //who had alleged that his wife died because of ... Consumer Disputes Redressal Commission Bench comprising Justice M B ... in its judgment, absolved five Kolkata-based doctors - Sukumar ...
... According to a study by Premera Blue Cross, it ... $1 billion to cover shortfalls incurred by hospitals and ... ,Gubby Barlow, chief executive officer of Mountlake ... cost-shifting. Others call it a hidden tax’. Thus it ...
... children get 'spellbound' in local contests every year with 275 ... it// to the finals of the prestigious Scripps National Spelling ... ,With the bee's soaring popularity, the championship round will ... first time as 139 boys and 136 girls, making up ...
... hospitals in Delhi were once again buzzing with activity ... , who called off their nearly three-week-long anti-quota strike ... services were showing signs of normalcy with patients thronging ... Sciences, Safdarjung, Maulana Azad Medical College, Ram Manohar Lohia ...
... introduction of a UN AIDS report, UN officials were prompted ... in Myanmar and Vietnam // , which is inadequate prevention ... was originally a HIV/AIDS haven, has shown remarkable decline in ... measures to combat AIDS go slack, there is a risk ...
Cached Medicine News:Health News:High Doses Of Common Pain killers Can Double The Chances Of Heart attack 2Health News:Indian Americans Compete for the Prestigious Spelling Bee Contest 2